— Know what they know.
Not Investment Advice
Also trades as: PHASQ (OTC) · $vol 0M

PHAS NASDAQ

PhaseBio Pharmaceuticals, Inc.
1W: -42.4% 1M: -62.8% 3M: -94.3% 1Y: -98.3% 3Y: -98.4%
$0.07
Last traded 2022-11-02 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$47M +20.9% ▲
Capital Expenditures
$3M -89.7% ▼
5Y CAGR: +95.4%
Free Cash Flow
-$50M +18.4% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$14M +129.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
— Operating Activities —
Net Income-$10M-$24M-$39M-$99M-$131K
Depreciation & Amort.$96K$105K$174K$508K$2M
Stock-Based Comp.$77K$332K$1M$2M$2M
Change in Working Capital$66K$2M-$2M-$4M$29M
Other Non-Cash Items$2M$4M$500K$40M-$81M
Operating Cash Flow-$8M-$17M-$40M-$60M-$47M
— Investing Activities —
Capital Expenditures-$216K-$119K-$960K-$1M-$3M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$0$0$0$0$0
Investing Cash Flow-$216K-$119K-$960K-$1M-$3M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$18M$65M$54M$15M$64M
Financing Cash Flow$18M$65M$54M$15M$64M
Net Change in Cash$10M$48M$13M-$46M$14M
Cash End of Period$13M$61M$74M$28M$42M
Free Cash Flow-$8M-$17M-$41M-$61M-$50M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms